Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$171.94 USD

171.94
456,301

+0.91 (0.53%)

Updated May 17, 2024 04:00 PM ET

After-Market: $171.93 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag

by Zacks Equity Research

Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.

AstraZeneca's (AZN) Ultomiris sBLA Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.

Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal

by Zacks Equity Research

Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.

Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline

by Zacks Equity Research

Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.

Repligen (RGEN) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.

bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review

by Zacks Equity Research

bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.

Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.

Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline

by Zacks Equity Research

Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RFG

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IVOG

Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up

by Zacks Equity Research

Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen's (RGEN) Q3 Earnings & Sales Beat Estimates

by Zacks Equity Research

Repligen (RGEN) beats earnings and sales estimates in the third quarter of 2021.

Repligen (RGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

Repligen (RGEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

by Zacks Equity Research

Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.

bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia

by Zacks Equity Research

bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ¿¿-thalassemia.

AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.

Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

by Zacks Equity Research

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

by Zacks Equity Research

Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.

aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923

by Zacks Equity Research

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.